You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 10, 2025

CLINICAL TRIALS PROFILE FOR NATRECOR


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Natrecor

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00075179 ↗ Natrecor in Pulmonary Hypertension Terminated M.D. Anderson Cancer Center Phase 4 2003-12-31 The goal of this clinical research study is to learn if the drug nesiritide (Natrecor) is effective in lowering the pressure in your lungs. The primary objective of this study is to establish that Nesiritide (Natrecor) is effective in reducing pulmonary hypertension (PHTN) acutely as measured by a 20% reduction in the mean pulmonary arterial (PA) pressure. The secondary objectives will include: improvement in pulmonary vascular resistance (PVR), patient symptoms, exercise tolerance, frequency of toxicity, and surgeon's willingness to proceed with operation.
NCT00083772 ↗ Use of Nesiritide in the Management of Acute Diastolic Heart Failure Terminated M.D. Anderson Cancer Center Phase 4 2004-05-17 Primary objective is to assess the effect of nesiritide in decreasing left ventricular (LV) filling pressure, defined as pulmonary artery capillary wedge pressure (PCWP) in a group of patients admitted with acute diastolic heart failure. Secondary objectives include: improvement in symptoms, exercise tolerance, improvement in Doppler diastolic filling parameters in patients with diastolic heart failure.
NCT00091520 ↗ A Study of the Safety and Efficacy of Follow-up Serial Infusions of Natrecor(Nesiritide) for the Management of Patients With Heart Failure Completed Scios, Inc. Phase 2 2004-04-01 The purpose of this study is to evaluate the efficacy and safety of Nesiritide administered as serial infusions to heart failure (HF) patients in the outpatient setting.
NCT00119691 ↗ Nesiritide Infusion for the Treatment of Decompensated Heart Failure and Renal Dysfunction Completed Scios, Inc. Phase 2 2003-04-01 The researchers hypothesize that the addition of nesiritide to standard therapy will prevent worsening of renal function in patients admitted to the hospital with decompensated heart failure and renal dysfunction relative to standard therapy alone.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Natrecor

Condition Name

Condition Name for Natrecor
Intervention Trials
Congestive Heart Failure 11
Heart Failure, Congestive 7
Heart Failure 4
Renal Insufficiency 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Natrecor
Intervention Trials
Heart Failure 24
Renal Insufficiency 4
Cardiomyopathies 4
Hypertension 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Natrecor

Trials by Country

Trials by Country for Natrecor
Location Trials
United States 36
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Natrecor
Location Trials
Minnesota 11
Massachusetts 4
California 3
Illinois 2
Texas 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Natrecor

Clinical Trial Phase

Clinical Trial Phase for Natrecor
Clinical Trial Phase Trials
Phase 4 8
Phase 3 7
Phase 2 7
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Natrecor
Clinical Trial Phase Trials
Completed 20
Terminated 12
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Natrecor

Sponsor Name

Sponsor Name for Natrecor
Sponsor Trials
Scios, Inc. 19
Mayo Clinic 8
National Center for Research Resources (NCRR) 6
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Natrecor
Sponsor Trials
Other 28
Industry 20
NIH 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

NATRECOR (Nesiritide): A Comprehensive Review of Clinical Trials, Market Analysis, and Projections

Introduction

Nesiritide, marketed under the brand name Natrecor, is a recombinant human B-type natriuretic peptide (BNP) used to treat acute decompensated heart failure (ADHF). Despite its initial promise, the drug has faced significant challenges and controversies. Here, we delve into the clinical trials, market analysis, and future projections for Natrecor.

Clinical Trials and Safety Concerns

Early Trials and Approval

Natrecor was first introduced with enthusiasm for its potential to improve dyspnea in patients with ADHF. The drug was approved by the FDA in 2001, following trials that showed it reduced filling pressures and improved symptoms in the short term[2].

ASCEND-HF Trial

The ASCEND-HF trial, one of the most significant studies on nesiritide, compared outcomes after IV nesiritide versus placebo infusion in patients with ADHF. The trial found that nesiritide was not associated with any change in mortality or renal function compared to the placebo group. However, it also indicated that there was no significant improvement in dyspnea or short-term clinical outcomes[4].

Safety Concerns

Despite the ASCEND-HF trial's findings, earlier meta-analyses by Sackner-Bernstein et al. raised concerns about the safety of nesiritide, suggesting an increased risk of renal dysfunction and mortality compared to non-inotrope-based control therapies. These findings led to revisions in the FDA-approved prescribing information, highlighting potential adverse effects on survival and kidney function[1].

Expert Panel and Regulatory Response

An expert panel convened in 2005 recommended further large-scale safety studies to assess the benefits and risks of Natrecor. The Centers for Medicare & Medicaid Services (CMS) determined that the use of nesiritide for chronic heart failure was not reasonable and necessary for Medicare beneficiaries. The European Agency for the Evaluation of Medicinal Products also did not approve nesiritide, awaiting more definitive trial results[1][2].

Market Performance and Challenges

Initial Success and Decline

Natrecor saw significant commercial success in its first year on the market, with sales over $107 million. However, following the publication of safety concerns in 2005, the drug's reputation and sales plummeted. Media coverage exacerbated the situation, leading to a substantial decline in its use[2].

Impact of Safety Criticism

The safety criticisms, although based on retrospective analyses that were later disputed, had a lasting impact on Natrecor's market performance. The FDA advisory committee's recommendation for a large safety study was not acted upon promptly by Scios, the original developer, which further eroded confidence in the drug. Johnson & Johnson, which acquired Scios, eventually faced a subpoena for documents related to the sales and marketing of Natrecor, marking the beginning of the end for Scios and the drug's commercial viability[2].

Market Analysis and Projections

Current Market Status

The global market for nesiritide acetate has been impacted significantly by the safety concerns and lack of strong clinical evidence supporting its use. The market size, which was once promising, has stagnated due to these issues[5].

Forecast and Trends

The global nesiritide acetate market is not expected to see significant growth in the near future. The market analysis suggests that the drug's consumption and production will remain limited due to ongoing safety concerns and the lack of new clinical data to support its widespread use. The market is projected to expand at a modest CAGR, but it will likely remain a niche product with limited market share[5].

Competitive Landscape

The cardiovascular drug market is highly competitive, with other treatments such as levosimendan emerging as competitors to Natrecor. The failure of Natrecor to establish a strong clinical and safety profile has allowed other drugs to capture market share, further diminishing Natrecor's prospects[2].

Regulatory and Clinical Trial Landscape

Ongoing Research and Trials

While Natrecor is no longer a focal point for new clinical trials, there are ongoing studies examining its use in specific subgroups, such as patients undergoing high-risk cardiac surgery. However, these studies have not shown significant benefits in reducing the odds for dialysis or in-hospital mortality[1].

Regulatory Environment

The regulatory environment remains stringent, with the FDA and other agencies requiring robust safety and efficacy data before approving or recommending the use of any drug. The experience with Natrecor serves as a cautionary tale for pharmaceutical companies, highlighting the importance of thorough clinical trials and transparent data reporting[3].

Key Takeaways

  • Clinical Trials: Natrecor's clinical trials have shown mixed results, with some indicating safety concerns and others finding minimal clinical benefits.
  • Market Performance: The drug's market performance was initially strong but declined sharply following safety criticisms.
  • Market Projections: The global nesiritide acetate market is expected to grow at a modest CAGR, but its market share will remain limited.
  • Regulatory Environment: The regulatory landscape emphasizes the need for robust clinical data and safety profiles, which Natrecor has failed to establish convincingly.

FAQs

What is Natrecor used for?

Natrecor (nesiritide) is used to treat acute decompensated heart failure (ADHF), aiming to improve symptoms such as dyspnea.

What were the key findings of the ASCEND-HF trial?

The ASCEND-HF trial found that nesiritide was not associated with increased mortality or renal dysfunction but also did not significantly improve dyspnea or short-term clinical outcomes compared to a placebo.

Why did Natrecor's market performance decline?

Natrecor's market performance declined due to safety concerns raised by several studies and meta-analyses, which were amplified by media coverage and regulatory scrutiny.

Is Natrecor still used in clinical practice?

Natrecor is no longer widely used in clinical practice due to the lack of strong clinical evidence supporting its benefits and the presence of safety concerns.

What are the future prospects for Natrecor?

The future prospects for Natrecor are limited, with the drug expected to remain a niche product due to ongoing safety concerns and the lack of new clinical data to support its widespread use.

Sources

  1. Aetna: Nesiritide (Natrecor) - Medical Clinical Policy Bulletins.
  2. Clinical Leader: Lessons Learned From The Rise And Fall Of Scios.
  3. Biospace: U.S. Clinical Trials Market Size Industry Analysis Report, 2033.
  4. American College of Cardiology: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial - ASCEND-HF.
  5. Prof-Research: Nesiritide Acetate Market Size, Share, Trend and Forecast to 2025.

More… ↓

⤷  Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.